OrthoPediatrics (KIDS) opened Q1 2026 with revenue of US$59.4 million and a basic EPS loss of US$0.45, while trailing 12 month figures show revenue of US$243.3 million and a basic EPS loss of US$1.68 as the company continues to operate in the red. Over the past reported periods, revenue has moved from US$52.7 million in Q4 2024 to a range of roughly US$59 million to US$61.6 million through Q1 2026. Quarterly basic EPS has stayed loss making between about US$0.30 and US$0.69 per share. For investors, the latest print keeps the focus on how quickly margins can improve from current loss levels.

See our full analysis for OrthoPediatrics.

The next step is to set these results against the most common market narratives around OrthoPediatrics to see which stories line up with the numbers and which are challenged by the latest margin trends.

11.1% revenue growth but losses still heavy

• On a trailing 12 month basis, OrthoPediatrics generated US$243.3 million in revenue and recorded a net loss of US$39.7 million, which aligns with the 11.1% annual revenue growth figure but also with continued loss making operations.
• Supporters of the bullish narrative point to products like DF2 and the 3P platform as potential drivers of faster revenue and margin progress. However, the current trailing loss of US$39.7 million and Q1 2026 net loss of US$10.7 million highlight that any push toward the bullish case of positive earnings still sits against a backdrop of ongoing negative profitability.
  • For example, bulls talk about long term earnings momentum, while the last six reported quarters all show quarterly net losses between about US$7.1 million and US$16.1 million.
  • That contrast means anyone leaning toward the bullish view is effectively assuming a shift away from the recent pattern of losses, rather than seeing it in the reported numbers yet.

Bulls argue that Q1 revenue traction and product ramps could be an early step toward their long term case, but the current loss profile forces you to weigh that optimism against what is still on the income statement.🐂 OrthoPediatrics Bull Case

Five year loss trend backs cautious view

• Over the past five years, losses have expanded at about a 20.1% annual rate and analysts expect OrthoPediatrics to remain unprofitable over the next three years, while Q1 2026 Basic EPS of US$0.45 loss and trailing 12 month EPS of US$1.68 loss fit that pattern.
• Critics in the bearish camp focus on this long history of loss making and on cost pressures, and the recent data support that concern with Q1 2026 net income at a US$10.7 million loss and trailing 12 month net income at a US$39.7 million loss despite the 11.1% revenue growth rate.
  • Bearish commentary also highlights rising operating expenses and clinic expansion costs, which is consistent with the observation that losses remain sizeable across all six quarters shown, even as revenue sits in the US$52 million to US$62 million range per quarter.
  • Put alongside forecasts for ongoing unprofitability, the historical 20.1% annual increase in losses gives bears concrete evidence that cost growth has outpaced revenue in recent years.

Skeptics argue that the combination of a five year loss trend and no forecasted return to profitability keeps the burden of proof on the company to show that new investments will translate into better earnings over time.🐻 OrthoPediatrics Bear Case

P/S discount sits against persistent losses

• OrthoPediatrics trades on a P/S of 1.7x, compared with a peer average of 1.8x and a US Medical Equipment industry average of 2.8x, while the trailing 12 month loss of US$39.7 million and current share price of US$15.63 explain why the valuation still reflects a loss making profile.
• Analysts who see relative value in the stock point to this P/S discount as a potential reward. At the same time, the valuation work also flags major risks around ongoing unprofitability and recent insider selling, so the lower multiple sits alongside the reality that the business has not produced profits in the trailing period.
  • The 11.1% trailing revenue growth rate lines up with the broader US market growth rate, so the P/S gap is not tied to obviously weaker top line performance but rather to the sustained net losses.
  • Recent significant insider selling over the last three months is another data point investors may weigh when deciding whether the P/S discount is compensation for risk or a sign that expectations remain cautious.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for OrthoPediatrics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed signals on growth, losses and valuation can be hard to unpack, so review the numbers yourself, weigh both sides and see how they compare with the 1 key reward and 2 important warning signs

See What Else Is Out There

OrthoPediatrics combines a five year trend of expanding losses, continued unprofitable quarters and insider selling, so the current P/S discount still comes with meaningful risk.

If that mix of ongoing losses and valuation questions feels uncomfortable, compare it with companies that prioritize resilience and steadier fundamentals using the 67 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.